Security
Century Therapeutics, Inc. Common Stock · IPSC
IPSCNASDAQCommon stockCurrentCIK 1850119Updated Oct 6, 2026
IPSC price & chart
Loading TradingView…
NASDAQ:IPSC on TradingView ↗About the company
Century Therapeutics (NASDAQ: IPSC) is a biotechnology company advancing a pipeline of iPSC-derived cell therapies with the potential to meaningfully address autoimmune diseases, including T1D, and cancer. Century's therapies are derived from its iPSC cell foundry and leverage its novel immune evasion engineering technology, Allo-Evasion™. Century believes its approach to developing off-the-shelf cell therapies will expand patient access and provide advantages over existing cell therapies which will ultimately advance the course of care. For more information on Century Therapeutics, please visit www.centurytx.com and connect with us on LinkedIn.
In the news
Century Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates ↗
Recent filings
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
144 filing
144 filing
4 filing
3 filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 244,717,000Source | 388,617,000Source | 287,006,000Source | 284,692,000Source | 416,446,000Source | 326,553,000Source | 315,609,000Source | 348,507,000Source | 223,704,000Source | 353,216,000Source | 360,691,000Source | 486,544,000Source |
| Property, Plant and Equipment, NetUSD | 53,715,000Source | 65,284,000Source | 34,482,000Source | 56,649,000Source | 69,405,000Source | 47,606,000Source | 59,532,000Source | 69,005,000Source | 50,026,000Source | 62,141,000Source | 71,705,000Source | 82,785,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 34,200,000Source | 33,800,000Source | 34,200,000Source | 34,200,000Source | 33,300,000Source | 34,200,000Source | 34,200,000Source | — | 34,200,000Source | 34,200,000Source | — | — |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 55,515,000Source | 52,593,000Source | 49,642,000Source | 56,878,000Source | 41,457,000Source | 51,048,000Source | 51,865,000Source | 46,812,000Source | 61,853,000Source | 58,441,000Source | 47,324,000Source | 84,265,000Source |
| Assets, CurrentUSD | 137,709,000Source | 206,009,000Source | 124,768,000Source | 160,169,000Source | 203,478,000Source | 139,039,000Source | 169,631,000Source | 199,813,000Source | 120,769,000Source | 194,051,000Source | 176,994,000Source | 319,721,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 4,960,000Source | 7,897,000Source | 5,056,000Source | 4,326,000Source | 7,076,000Source | 4,236,000Source | 4,510,000Source | 7,797,000Source | 3,655,000Source | 4,759,000Source | 4,256,000Source | 4,003,000Source |
| Operating Lease, Right-of-Use AssetUSD | 16,566,000Source | 28,828,000Source | 13,513,000Source | 27,737,000Source | 28,570,000Source | 20,972,000Source | 28,232,000Source | 19,314,000Source | 16,139,000Source | 28,706,000Source | 20,376,000Source | 28,945,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 68,369,000Source | 192,931,000Source | 54,661,000Source | 74,794,000Source | 194,342,000Source | 61,809,000Source | 75,170,000Source | 170,624,000Source | 64,768,000Source | 191,854,000Source | 175,941,000Source | 183,806,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 9,000Source | 9,000Source | 18,000Source | 9,000Source | 8,000Source | 18,000Source | 9,000Source | 6,000Source | 9,000Source | 9,000Source | 6,000Source | 6,000Source |
| Retained Earnings (Accumulated Deficit)USD | -772,740,000Source | -746,266,000Source | -848,112,000Source | -738,318,000Source | -715,040,000Source | -813,562,000Source | -705,777,000Source | -683,833,000Source | -791,917,000Source | -782,337,000Source | -655,771,000Source | -519,098,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 64,000Source | 758,000Source | -694,000Source | 83,000Source | -309,000Source | -585,000Source | 305,000Source | -241,000Source | 30,000Source | 324,000Source | 108,000Source | -2,462,000Source |
| Stockholders' Equity Attributable to ParentUSD | 176,348,000Source | 195,686,000Source | 232,345,000Source | 209,898,000Source | 222,104,000Source | 264,744,000Source | 240,439,000Source | 177,883,000Source | 158,936,000Source | 161,362,000Source | 184,750,000Source | 302,738,000Source |
| Additional Paid in Capital, Common StockUSD | 949,015,000Source | 941,185,000Source | 1,081,133,000Source | 948,124,000Source | 937,445,000Source | 1,078,873,000Source | 945,902,000Source | 861,951,000Source | 950,814,000Source | 943,366,000Source | 840,407,000Source | 824,292,000Source |
| Liabilities and EquityUSD | 244,717,000Source | 388,617,000Source | 287,006,000Source | 284,692,000Source | 416,446,000Source | 326,553,000Source | 315,609,000Source | 348,507,000Source | 223,704,000Source | 353,216,000Source | 360,691,000Source | 486,544,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 22,026,000Source | 19,820,000Source | 15,068,000Source | 14,948,000Source | 19,163,000Source | 13,566,000Source | 14,503,000Source | 16,065,000Source | 20,226,000Source | 129,782,000Source | 17,846,000Source | 29,817,000Source |
| Operating Lease, Liability, CurrentUSD | 3,772,000Source | 3,759,000Source | 4,040,000Source | 4,894,000Source | 3,663,000Source | 4,083,000Source | 4,882,000Source | 2,215,000Source | 3,324,000Source | 4,870,000Source | 1,513,000Source | 475,000Source |
| Accounts Payable, CurrentUSD | 2,617,000Source | 2,598,000Source | 4,823,000Source | 3,208,000Source | 3,358,000Source | 3,150,000Source | 3,573,000Source | 3,432,000Source | 4,773,000Source | 3,075,000Source | 2,741,000Source | 5,454,000Source |
| Operating Lease, Liability, NoncurrentUSD | 41,185,000Source | 50,837,000Source | 34,626,000Source | 46,589,000Source | 52,713,000Source | 43,942,000Source | 47,793,000Source | 44,251,000Source | 40,241,000Source | 48,960,000Source | 46,658,000Source | 38,698,000Source |
| Deferred Income Tax Liabilities, NetUSD | 4,374,000Source | 3,503,000Source | 4,301,000Source | 4,374,000Source | 3,366,000Source | 4,301,000Source | 4,374,000Source | — | 4,301,000Source | 4,374,000Source | 10,388,000Source | 11,303,000Source |
| Additional Financial Items | ||||||||||||
| Deferred Revenue, CurrentUSD | — | 3,569,000Source | — | — | 4,360,000Source | — | — | 4,610,000Source | — | 109,164,000Source | 4,372,000Source | 7,154,000Source |
| Deferred Revenue, NoncurrentUSD | — | 109,768,000Source | — | — | 109,768,000Source | — | — | 110,288,000Source | — | — | 111,381,000Source | 110,834,000Source |
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | 4,301,000Source | 4,374,000Source | — | 5,000Source |
| Long-term Debt, Excluding Current Maturities | — | — | — | — | — | — | — | — | — | — | — | —Source |
| Long-term Debt, Excluding Current MaturitiesUSD | — | — | — | — | — | — | — | — | — | — | — | 3,739,000Source |
| Short-term InvestmentsUSD | 77,234,000Source | 145,519,000Source | 70,070,000Source | 98,965,000Source | 154,945,000Source | 83,755,000Source | 113,256,000Source | 145,204,000Source | 55,261,000Source | 130,851,000Source | 125,414,000Source | 231,233,000Source |
| Goodwill | — | —Source | — | — | —Source | — | — | — | — | — | — | — |
| Other Liabilities, Noncurrent | — | — | —Source | — | — | — | — | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -21,645,000Source | 76,560,000Source | -9,580,000Source | -126,566,000Source | -136,673,000Source | -130,932,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 1,445,000Source | 2,426,000Source | 6,840,000Source | 12,688,000Source | 14,622,000Source | 10,669,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | -1,625,000Source | 361,000Source | 1,562,000Source | -1,469,000Source | -2,361,000Source | -4,788,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | -73,000Source | 869,000Source | -3,000Source | 5,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -25,262,000Source | -34,623,000Source | -103,876,000Source | -110,135,000Source | -88,348,000Source | 14,052,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -112,615,000Source | 27,930,000Source | 107,501,000Source | 47,482,000Source | 61,132,000Source | -13,128,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 584,000Source | 475,000Source | 848,000Source | 154,000Source | 13,736,000Source | 30,604,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 126,623,000Source | 120,000Source | 173,000Source | 74,563,000Source | -9,725,000Source | 27,158,000Source |
| Repayments of Long-term DebtUSD | — | — | — | — | — | — | — | — | — | — | 10,241,000Source | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 58,674,000Source | 55,432,000Source | 52,001,000Source | 59,587,000Source | 53,757,000Source | 54,640,000Source | 65,011,000Source | 61,213,000Source | 49,303,000Source | 86,244,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | — | — | — | — | 586,000Source | 1,097,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 891,000Source | 3,318,000Source | 1,950,000Source | 2,222,000Source | 1,445,000Source | 2,426,000Source | 6,840,000Source | 12,688,000Source | 14,622Source | 10,669,000Source |
| Amortization of Debt Issuance CostsUSD | — | — | — | — | — | — | — | — | — | — | 94,000Source | 299,000Source |
| DepreciationUSD | — | — | 3,129,000Source | 3,297,000Source | 26,000Source | 3,201,000Source | 3,004,000Source | 3,221,000Source | 13,101,000Source | 13,304,000Source | 13,044,000Source | 8,440,000Source |
| Gain (Loss) on Termination of LeaseUSD | — | — | — | — | -11,145,000Source | — | — | — | 1,395,000Source | — | — | — |
| General and Administrative ExpenseUSD | — | — | 6,835,000Source | 8,352,000Source | 5,787,000Source | 7,805,000Source | 6,579,000Source | 8,408,000Source | 24,003,000Source | 33,155,000Source | 34,706,000Source | 31,857,000Source |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | — | — | — | 4,327,000Source | — | — |
| Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)USD | — | — | 0Source | — | — | — | 0Source | 0Source | 0Source | 0Source | — | — |
| Income Tax Expense (Benefit)USD | — | — | — | -8,000Source | — | — | — | — | -68,000Source | 1,790,000Source | 1,881,000Source | 91,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -34,422,000Source | -31,226,000Source | -34,550,000Source | -32,541,000Source | -21,645,000Source | 76,560,000Source | -9,580,000Source | -126,566,000Source | -136,673,000Source | -130,932,000Source |
| Nonoperating Income (Expense)USD | — | — | 1,702,000Source | 3,555,000Source | 1,977,000Source | 2,123,000Source | 2,039,000Source | 2,384,000Source | 7,621,000Source | 13,361,000Source | 11,754,000Source | — |
| Operating ExpensesUSD | — | — | 36,124,000Source | 35,580,000Source | 36,527,000Source | 34,664,000Source | 23,684,000Source | 34,988,000Source | 126,433,000Source | 144,726,000Source | 148,781,000Source | 139,030,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 97,000Source | 250,000Source | -5,000Source | 113,000Source | 20,000Source | -38,000Source | 275,000Source | 354,000Source | — | 2,990,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | 202,000Source | 120,000Source | 173,000Source | 141,000Source | 516,000Source | 345,000Source |
| Goodwill | — | — | — | —Source | — | — | — | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | — | 791,000Source | — | — | — | 109,164,000Source | 109,164,000Source | 6,589,000Source | 2,235,000Source | 5,199,000Source |
| Operating Income (Loss)USD | — | — | -36,124,000Source | -34,789,000Source | -36,527,000Source | -34,664,000Source | -23,684,000Source | 74,176,000Source | -17,269,000Source | -138,137,000Source | -146,546,000Source | -133,831,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 97,000Source | 250,000Source | -5,000Source | 113,000Source | 20,000Source | -38,000Source | 275,000Source | 354,000Source | — | 2,990,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -34,422,000Source | -31,234,000Source | — | -32,541,000Source | — | 76,560,000Source | -9,648,000Source | -124,776,000Source | -134,792,000Source | -130,841,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | -8,000Source | — | — | — | — | -68,000Source | 1,790,000Source | 1,881,000Source | 91,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -34,422,000Source | -31,226,000Source | -34,550,000Source | -32,541,000Source | -21,645,000Source | 76,560,000Source | -9,580,000Source | -126,566,000Source | -136,673,000Source | -130,932,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.4Source | -0.37Source | -0.17Source | -0.38Source | -0.11Source | 0.89Source | -0.14Source | -1.61Source | -2.3Source | -2.27Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.4Source | -0.37Source | -0.17Source | -0.38Source | -0.11Source | 0.89Source | -0.14Source | -1.61Source | -2.27Source | -2.27Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 86,464,066Source | 84,704,352Source | 205,778,156Source | 86,238,084Source | 193,474,913Source | 86,021,188Source | 86,556,515Source | 78,648,958Source | 59,314,389Source | 57,755,842Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 86,464,066Source | 84,704,352Source | 205,778,156Source | 86,238,084Source | 193,474,913Source | 86,098,619Source | 86,556,515Source | 78,648,958Source | 57,755,842Source | 57,755,842Source |
| Additional Financial Items | ||||||||||||
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 5,000Source | 921,000Source | 1,884,000Source | 86,000Source |
| General and Administrative ExpenseUSD | — | — | 6,835,000Source | 8,352,000Source | 5,787,000Source | 7,805,000Source | 6,579,000Source | 8,408,000Source | 24,003,000Source | 33,155,000Source | 34,706,000Source | 31,857,000Source |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | — | — | — | 4,327,000Source | — | — |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -9,692,000Source | -124,781,000Source | -135,003,000Source | -131,314,000Source |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 540,000Source | 1,404,000Source |
| Interest Expense, DebtUSD | — | — | — | — | — | — | — | — | — | — | 540,000Source | 1,105,000Source |
| Interest Income, OtherUSD | — | — | 1,605,000Source | 3,305,000Source | 1,982,000Source | 2,010,000Source | 2,019,000Source | 2,422,000Source | 7,346,000Source | 13,007,000Source | — | — |
| Nonoperating Income (Expense)USD | — | — | 1,702,000Source | 3,555,000Source | 1,977,000Source | 2,123,000Source | 2,039,000Source | 2,384,000Source | 7,621,000Source | 13,361,000Source | 11,754,000Source | — |
| Operating ExpensesUSD | — | — | 36,124,000Source | 35,580,000Source | 36,527,000Source | 34,664,000Source | 23,684,000Source | 34,988,000Source | 126,433,000Source | 144,726,000Source | 148,781,000Source | 139,030,000Source |
| Research and Development Expense | — | — | —Source | — | — | — | — | — | — | — | — | — |
Offerings
Registration 333-293228
Registration 333-288616
Filing attachments
tm2626840d1_ex99-1.htm · 8-K · 2026-10-02
Exhibit 99.1 Century Therapeutics' CNTY-813 Demonstrates Continued Advancement Toward the Clinic Via Nonclinical Data Presented at EASD 2026 Data demonstrated scalable production, in vivo function and immune evasion, and updated progress toward clinical dosing of CNTY-813, Century's iPSC-derived islet replacement therapy for type 1 diabetes CNTY-813 IND submission remains on track for Q4 2026; initial clinical data anticipated in the second half of 2027 PHILADELPHIA, October 2nd, 2026 (GLOBE…
Read attachment ↗tm2626840d1_ex99-2.htm · 8-K · 2026-10-02
Exhibit 99.2 CNTY - 813: Scalable Production of Allo - Evasion TM 5.0 - Engineered iPSC Islets for Off - the - Shelf Cell Therapies G. Grant Welstead, PhD SVP, Head of Research 2 Disclosures Presenter G. Grant Welstead, PhD Relevant Financial Relationship • Employee, Century Therapeutics Presentation Information • This presentation describes preclinical research related to CNTY - 813, an investigational iPSC - derived islet cell therapy for T1D • The content is intended for scientific and educ…
Read attachment ↗tm2625030d1_ex99-1.htm · 8-K · 2026-09-09
EX-99.1 2 tm2625030d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Century Therapeutics Appoints Joseph Truitt to Board of Directors PHILADELPHIA, September 9, 2026 - Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes (T1D), and cancer, today announced the appointment of Joseph Truitt to its Board of Directors. Truitt currently serves as Chief Execut…
Read attachment ↗tm2622911d1_ex99-1.htm · 8-K · 2026-08-12
EX-99.1 2 tm2622911d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Century Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates Completed pre-IND meeting with the FDA for CNTY-813, an iPSC-derived islet replacement therapy with functional cure potential in type 1 diabetes (T1D); IND submission on track for 4Q 2026 CNTY-813 preclinical data from oral presentation at ADA 2026 showed durable glucose control in vivo, immune evasion, and manufacturing success at clin…
Read attachment ↗tm2622911d1_ex99-2.htm · 8-K · 2026-08-12
EX-99.2 3 tm2622911d1_ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 Advancing Curative Medicines Through Cell Engineering August 2026 ──────────────────────────────── 2 Forward-looking statements This presentation contains forward-looking statements within the meaning of, and made pursuant to the safe harbor provisions of, The Private Securities Litigation Reform Act of 1995. All statements contained in this presentation, other than statements of historical facts or statements that r…
Read attachment ↗tm2617028d1_ex99-1.htm · 8-K · 2026-06-08
EX-99.1 2 tm2617028d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 New CNTY-813 Preclinical Data Demonstrate Durable Glucose Control, Immune Evasion Under Alloimmune Pressure, and Scalable Manufacturing at ADA 2026 Advancing CNTY-813 as a potential functional cure in Type 1 Diabetes ──────────────────────────────────────────────────────────────────────── CNTY-813 iPSC-derived islet replacement therapy demonstrates durable in-vivo glucose control maintained for more than eight months in pre…
Read attachment ↗